The new list of Top 200 Nottinghamshire companies has just been published by the Nottingham Post. It shows Potter Clarkson, which was at 149 a couple of years ago, now at 134 with our £30m turnover from 2017.
Stephen McNeeney, partner and pharmaceuticals expert, comments on the news that Orexo AB has won its patent appeal with Teva over its Zubsolv opioid addiction drug.
As part of its expansion plans in the Nordic region, Potter Clarkson is delighted to announce the opening of a new office in Copenhagen and its forthcoming move to larger premises in Stockholm.
In a debate in the House of Commons on 19 July, Robin Walker MP, the Parliamentary Under-Secretary of State for Exiting the European Union, has expressly stated that conversion of all existing EU trade marks, Community registered designs and unregistered designs will be “automatic and free”.
On 25 July 2018, the Court of Justice of the European Union handed down a judgment in Teva v Gilead concerning Supplementary Protection Certificates and, in particular, what determines whether a product comprising a combination of active ingredients is "protected by a basic patent".
With the rapid rise of the additive manufacturing sector, it has become increasingly possible for industry players to make spare and replacement parts in a cost-effective manner.